Trametinib and inhibitor evaluation

Trametinib (GSK1120212), MK2206 (PubChem compound database (CID, 24964624)), GDC0032 (25 (link)), TGX221 (26 (link)), BYL710 (25 (link)) and IPI145 (25 (link)) were purchased from Selleck Chemicals (Houston, TX). Recombinant human HGF was purchased from PeproTech (Rocky Hill, NJ) and used at 10 ng/ml based on our previous studies (20 (link)). The neutralizing and internalizing anti-cMET antibody, LY2875358, and the cMET/RON inhibitor, LY2801653 (27 ), were provided by Eli Lilly and Company (Indianapolis, IN).

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Cheng H., Chua V., Liao C., Purwin T.J., Terai M., Kageyama K., Davies M.A., Sato T, & Aplin A.E. (2017). Co-targeting HGF-cMET signaling with MEK inhibitors in metastatic uveal melanoma. Molecular cancer therapeutics, 16(3), 516-528.

Publication 2016

Trametinib MK2206 GDC0032 TGX221 IPI145 Recombinant human HGF LY2801653

Anti antibody Cmet Gdc0032 Gsk1120212 Human Ly2801653 Ly2875358 Mk2206 Trametinib

Corresponding Organization : Thomas Jefferson University

Other organizations : The University of Texas MD Anderson Cancer Center

Top 5 similar protocols

Variable analysis

independent variables

Trametinib (GSK1120212)
MK2206 (PubChem compound database (CID, 24964624))
GDC0032 (25 (link))
TGX221 (26 (link))
BYL710 (25 (link))
IPI145 (25 (link))
Recombinant human HGF
LY2875358 (neutralizing and internalizing anti-cMET antibody)
LY2801653 (cMET/RON inhibitor)

dependent variables

Not explicitly mentioned

control variables

Not explicitly mentioned

positive controls

Recombinant human HGF (used at 10 ng/ml based on previous studies (20 (link)))

negative controls

Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!